Literature DB >> 30023123

MetaLanc9 as a novel biomarker for non-small cell lung cancer: promising treatments via a PGK1-activated AKT/mTOR pathway.

Ramon Andrade De Mello1,2,3, Pedro Nazareth Aguiar4, Hakaru Tadokoro5, Tállita Meciany Farias-Vieira6, Pedro Castelo-Branco1, Gilberto de Lima Lopes7, Daniel Humberto Pozza2,8.   

Abstract

Entities:  

Year:  2018        PMID： 30023123      PMCID： PMC6036006          DOI： 10.21037/jtd.2018.04.122

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  15 in total

1.  Brief report: a phase II "window-of-opportunity" frontline study of the MTOR inhibitor, temsirolimus given as a single agent in patients with advanced NSCLC, an NCCTG study.

Authors:  Thanyanan Reungwetwattana; Julian R Molina; Sumithra J Mandrekar; Katie Allen-Ziegler; Kendrith M Rowland; Nicholas F Reuter; Ronnie F Luyun; Grace K Dy; Randolph S Marks; Steven E Schild; James R Jett; Alex A Adjei
Journal:  J Thorac Oncol       Date:  2012-05       Impact factor: 15.609

2.  Cancer statistics, 2018.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-01-04       Impact factor: 508.702

3.  Phase I study of temsirolimus in combination with EKB-569 in patients with advanced solid tumors.

Authors:  Alan H Bryce; Ravi Rao; Jann Sarkaria; Joel M Reid; Yingwei Qi; Rui Qin; C David James; Robert B Jenkins; Joseph Boni; Charles Erlichman; Paul Haluska
Journal:  Invest New Drugs       Date:  2011-09-01       Impact factor: 3.850

4.  Phase I trial of everolimus in combination with thoracic radiotherapy in non-small-cell lung cancer.

Authors:  E Deutsch; C Le Péchoux; L Faivre; S Rivera; Y Tao; J-P Pignon; M Angokai; R Bahleda; D Deandreis; E Angevin; C Hennequin; B Besse; A Levy; J-C Soria
Journal:  Ann Oncol       Date:  2015-02-20       Impact factor: 32.976

5.  Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall-cell lung cancer.

Authors:  Daniel T Milton; Gregory J Riely; Christopher G Azzoli; Jorge E Gomez; Robert T Heelan; Mark G Kris; Lee M Krug; William Pao; Barbara Pizzo; Naiyer A Rizvi; Vincent A Miller
Journal:  Cancer       Date:  2007-08-01       Impact factor: 6.860

6.  Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies.

Authors:  Monica M Mita; Alain C Mita; Quincy S Chu; Eric K Rowinsky; Gerald J Fetterly; Michelle Goldston; Amita Patnaik; Lesley Mathews; Alejandro D Ricart; Theresa Mays; Heather Knowles; Victor M Rivera; Jeff Kreisberg; Camille L Bedrosian; Anthony W Tolcher
Journal:  J Clin Oncol       Date:  2008-01-20       Impact factor: 44.544

7.  Everolimus and erlotinib as second- or third-line therapy in patients with advanced non-small-cell lung cancer.

Authors:  Vassiliki A Papadimitrakopoulou; Jean-Charles Soria; Annette Jappe; Valentine Jehl; Judith Klimovsky; Bruce E Johnson
Journal:  J Thorac Oncol       Date:  2012-10       Impact factor: 15.609

8.  Phase II study of docetaxel in combination with everolimus for second- or third-line therapy of advanced non-small-cell lung cancer.

Authors:  Suresh S Ramalingam; Taofeek K Owonikoko; Madhusmita Behera; Janakiraman Subramanian; Nabil F Saba; Scott A Kono; Anthony A Gal; Gabriel Sica; R Donald Harvey; Zhengjia Chen; Carmen M Klass; Dong M Shin; Haian Fu; Shi-yong R Sun; Ramaswamy Govindan; Fadlo R Khuri
Journal:  J Thorac Oncol       Date:  2013-03       Impact factor: 15.609

9.  Comparative outcome assessment of epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of advanced non-small-cell lung cancer: a network meta-analysis.

Authors:  Ramon Andrade De Mello; Carles Escriu; Pedro Castelo-Branco; Paloma Lucena Cabral; Giannis Mountzios; Gilberto de Lima Lopes; Pedro Madureira
Journal:  Oncotarget       Date:  2017-12-23

Review 10.  MicroRNAs in lung cancer.

Authors:  Diana Castro; Márcia Moreira; Alexandra Monteiro Gouveia; Daniel Humberto Pozza; Ramon Andrade De Mello
Journal:  Oncotarget       Date:  2017-09-16
View more
  5 in total

Review 1.  PGK1-mediated cancer progression and drug resistance.

Authors:  Yu He; Yang Luo; Dan Zhang; Xixi Wang; Peng Zhang; Haocheng Li; Samina Ejaz; Shufang Liang
Journal:  Am J Cancer Res       Date:  2019-11-01       Impact factor: 6.166

2.  Treatment Sequencing Strategies in Lung Cancer.

Authors:  Daniel Humberto Pozza; Ramon Bezerra Andrade de Mello
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2022-05-20

3.  PGK1 : An Essential Player in Modulating Tumor Metabolism.

Authors:  Leslie Duncan; Chloe Shay; Yong Teng
Journal:  Methods Mol Biol       Date:  2022

Review 4.  The Metabolism Reprogramming of microRNA Let-7-Mediated Glycolysis Contributes to Autophagy and Tumor Progression.

Authors:  Chien-Hsiu Li; Chiao-Chun Liao
Journal:  Int J Mol Sci       Date:  2021-12-22       Impact factor: 5.923

5.  Exosome-transferred LINC01559 promotes the progression of gastric cancer via PI3K/AKT signaling pathway.

Authors:  Liyan Wang; Xiaotong Bo; Xiaoyuan Yi; Xuhua Xiao; Qinghua Zheng; Lei Ma; Bin Li
Journal:  Cell Death Dis       Date:  2020-09-07       Impact factor: 8.469
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.